Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. filed Amendment No. 3 to their Schedule 13D for Opus Genetics, Inc. The filing reflects a reduced position of 3,792,171 shares of common stock, representing 4.66% of the company’s outstanding shares.
This change results from selling Opus Genetics common stock on May 18, 2026. Based on 81,395,539 shares outstanding as of May 7, 2026, the reporting persons now hold less than five percent and characterize this amendment as an exit filing ending their Schedule 13D reporting obligations.
Opus Genetics, Inc. director entities Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. reported an open-market sale of 1,700,000 shares of Common Stock of Opus Genetics at $4.35 per share.
The shares are owned directly by Foundation Fighting Blindness Retinal Degeneration Fund, whose board controls voting and investment decisions, while Foundation Fighting Blindness, Inc. is its sole member and may be deemed to beneficially own these securities. After the transaction, the reporting entities continue to hold 3,792,171 shares of Opus Genetics common stock.
Opus Genetics, Inc. ownership disclosure: Nantahala Capital Management, LLC and related reporting persons report beneficial ownership of 4,839,225 shares of Common Stock as of March 31, 2026. The filing states that 3,157,895 of those shares may be acquired within sixty days through the exercise of convertible securities. Each of Nantahala, Wilmot B. Harkey and Daniel Mack is reported as beneficially owning 6.51% of the outstanding shares, with shared voting and dispositive power over the 4,839,225 shares.
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund filed Amendment No. 2 to a Schedule 13G/A reporting 9.99% beneficial ownership of Opus Genetics, Inc. common stock.
The filing states the ownership percentages are calculated using 81,395,539 shares outstanding as of May 7, 2026 and assume exercise of Warrants that the Reporting Persons hold. The Master Fund directly holds 1,835,842 shares, Pre-Funded Warrants exercisable for 13,617,584 shares and Common Warrants exercisable for 13,157,895, subject to the "Beneficial Ownership Limitation." The limitation permits exercise for up to 6,994,303 shares under current conditions. Shared voting and dispositive power are reported as 8,830,145 shares for each Reporting Person.
Opus Genetics, Inc. ownership disclosure: Caligan Partners LP and David Johnson report beneficial ownership of 6,075,028 shares of common stock, representing 8.5% of the class. The percentage is calculated using 71,402,472 shares outstanding as of 03/31/2026, per cited filings.
The Schedule 13G names Caligan as the investment manager to certain funds and Mr. Johnson as Managing Partner; both signed the filing on 05/15/2026.
Balyasny Asset Management and affiliated reporting persons reported beneficial ownership of 5,110,373 shares of Opus Genetics Inc. Common Stock, representing approximately 7.18% of the class. This percentage is calculated from 71,149,045 Shares outstanding as of March 5, 2026.
The reported amount consists of 2,718,029 Shares and 2,392,344 Shares issuable upon exercise of 2,392,344 Warrants, with those Warrants subject to the Beneficial Ownership Limitation that prevents exercise to the extent ownership would exceed 9.99%.
Opus Genetics, Inc. Schedule 13G/A (Amendment No. 2) reports that certain affiliated investment vehicles and related managers collectively hold 3,683,429 shares of Common Stock, representing 4.53% of the class based on 81,395,539 shares outstanding as of May 7, 2026. The filing lists the chain of control that may give shared voting and dispositive power over those shares: Bios Fund III series, Bios Equity Partners III, Bios Management, Bios Advisors, and related Cavu entities, plus named individuals Aaron G.L. Fletcher and Leslie W. Kreis. The cover pages incorporated into Item 4 provide the amount beneficially owned and percent of class; signatures show counsel/attorney-in-fact execution on May 13, 2026.
Opus Genetics, Inc. Schedule 13G: Adage Capital Management and affiliated reporting persons report beneficial ownership of 6,029,775 shares of Common Stock, representing 8.47% of the class. The percentage is calculated using 71,149,045 shares outstanding as of March 5, 2026.
The statement attributes shared voting and dispositive power over the 6,029,775 shares to Adage entities and to reporting persons Robert Atchinson and Phillip Gross. The filing includes a joint filing agreement executed by the reporting persons.
Opus Genetics, Inc. reported sharply higher first‑quarter 2026 losses driven mainly by non‑cash warrant revaluation, while strengthening its cash position and advancing its gene therapy pipeline.
License and collaboration revenue from the Viatris agreement was $2.2 million, down from $4.4 million a year earlier as reimbursed R&D activity declined. Total operating expenses rose to $16.5 million, reflecting higher research and development spending of $10.6 million as clinical programs progressed.
The company recorded a net loss of $65.5 million versus $8.2 million in the prior‑year quarter, largely due to a $51.4 million fair value loss on warrant liabilities. Cash and cash equivalents increased to $60.0 million at March 31, 2026, helped by a $25.0 million Series B preferred stock financing and $2.3 million raised via the at‑the‑market program. Management states that, including approximately $34.5 million of April 2026 proceeds from a new Oberland Capital senior secured notes facility, available liquidity is expected to fund operations for at least 12 months. Opus continues to advance lead AAV gene therapy OPGx‑LCA5 toward a Phase 3 trial and is recruiting for OPGx‑BEST1, while maintaining multiple academic and foundation funding partnerships.
Opus Genetics reported first-quarter 2026 results and highlighted major pipeline progress in inherited retinal disease gene therapies. License and collaboration revenue was $2.2 million, down from $4.4 million a year earlier, reflecting lower reimbursed R&D activity. R&D expenses rose to $10.6 million while G&A declined slightly to $5.9 million.
Net loss widened sharply to $65.5 million, or $0.75 per share, mainly due to a large non-cash fair value loss on warrant liabilities, along with higher R&D spending. Cash and cash equivalents were about $60 million on March 31, 2026, and a new financing with Oberland Capital includes $35 million in senior secured notes and a planned $5 million equity investment. The company believes its current and potential funding will support operations into 2029.
Clinically, Opus reported strong six‑month pediatric data for OPGx-LCA5, FDA acceptance of LCA5 into the Rare Disease Evidence Principles program, and plans to start pivotal Phase 3 dosing in the fourth quarter of 2026. Topline Cohort 1 data for OPGx-BEST1 are expected in September 2026, while RDH12, MERTK, and RHO programs are slated to reach the clinic over the next one to two years.